Literature DB >> 15974936

Structure-activity relationships for the design of small-molecule inhibitors.

Adriano D Andricopulo1, Carlos A Montanari.   

Abstract

One of the most important stages of the drug discovery process is the generation of lead compounds. Structure-activity relationships (SAR) are well-integrated in modern drug discovery and have been largely used for the finding of new leads, scaffold generation, the optimization of receptor or enzyme affinity, as well as of pharmacokinetic and physicochemical properties. This review highlights some SAR approaches that can be used to optimize leads through a continuous, multi-step process based on knowledge gained at each stage, thus exploiting SAR in the design of selective, potent, small-molecule drug candidates.

Mesh:

Substances:

Year:  2005        PMID: 15974936     DOI: 10.2174/1389557054023224

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  11 in total

1.  Computational structure-activity relationship analysis of small-molecule agonists for human formyl peptide receptors.

Authors:  Andrei I Khlebnikov; Igor A Schepetkin; Mark T Quinn
Journal:  Eur J Med Chem       Date:  2010-09-15       Impact factor: 6.514

Review 2.  Fragment-based QSAR: perspectives in drug design.

Authors:  Lívia B Salum; Adriano D Andricopulo
Journal:  Mol Divers       Date:  2009-01-31       Impact factor: 2.943

3.  The bacterial type III secretion system as a target for developing new antibiotics.

Authors:  Andrew C McShan; Roberto N De Guzman
Journal:  Chem Biol Drug Des       Date:  2015-01       Impact factor: 2.817

4.  Computational structure-activity relationship analysis of non-peptide inducers of macrophage tumor necrosis factor-alpha production.

Authors:  Andrei I Khlebnikov; Igor A Schepetkin; Liliya N Kirpotina; Mark T Quinn
Journal:  Bioorg Med Chem       Date:  2008-09-05       Impact factor: 3.641

5.  Understanding electrostatic and steric requirements related to hypertensive action of AT(1) antagonists using molecular modeling techniques.

Authors:  Danielle da C Silva; Vinicius G Maltarollo; Emmanuela Ferreira de Lima; Karen Cacilda Weber; Kathia M Honorio
Journal:  J Mol Model       Date:  2014-06-17       Impact factor: 1.810

6.  Structure-activity relationship analysis of N-benzoylpyrazoles for elastase inhibitory activity: a simplified approach using atom pair descriptors.

Authors:  Andrei I Khlebnikov; Igor A Schepetkin; Mark T Quinn
Journal:  Bioorg Med Chem       Date:  2008-01-15       Impact factor: 3.641

7.  Fragment-based and classical quantitative structure-activity relationships for a series of hydrazides as antituberculosis agents.

Authors:  Carolina H Andrade; Livia de B Salum; Marcelo S Castilho; Kerly F M Pasqualoto; Elizabeth I Ferreira; Adriano D Andricopulo
Journal:  Mol Divers       Date:  2008-03-29       Impact factor: 2.943

Review 8.  Structural Mechanisms of Store-Operated and Mitochondrial Calcium Regulation: Initiation Points for Drug Discovery.

Authors:  Megan Noble; Qi-Tong Lin; Christian Sirko; Jacob A Houpt; Matthew J Novello; Peter B Stathopulos
Journal:  Int J Mol Sci       Date:  2020-05-21       Impact factor: 5.923

9.  Chemoinformatics Studies on a Series of Imidazoles as Cruzain Inhibitors.

Authors:  Alex R Medeiros; Leonardo L G Ferreira; Mariana L de Souza; Celso de Oliveira Rezende Junior; Rocío Marisol Espinoza-Chávez; Luiz Carlos Dias; Adriano D Andricopulo
Journal:  Biomolecules       Date:  2021-04-15

10.  Multiparameter Optimization of Trypanocidal Cruzain Inhibitors With In Vivo Activity and Favorable Pharmacokinetics.

Authors:  Ivani Pauli; Celso de O Rezende; Brian W Slafer; Marco A Dessoy; Mariana L de Souza; Leonardo L G Ferreira; Abraham L M Adjanohun; Rafaela S Ferreira; Luma G Magalhães; Renata Krogh; Simone Michelan-Duarte; Ricardo Vaz Del Pintor; Fernando B R da Silva; Fabio C Cruz; Luiz C Dias; Adriano D Andricopulo
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.